View More View Less
  • 1 Richter Gedeon Nyrt., , Budapest, Magyarország; Gedeon Richter Plc., , Budapest, Hungary
Open access

Összefoglaló. A tavalyi évben kitört COVID–19 pandémia jelentős kihívások elé állította a világot. Nem pusztán a kormányok és az egészségügyi rendszerek szembesültek új, békeidőben eddig még nem gyakorolt feladatokkal, de a tudományos világnak is át kellett tekinteni mind a régi, mind a legmodernebb eszközöket ahhoz, hogy a vírus terjedésének, a betegek szenvedéseinek, a tömeges halálozásoknak végre véget lehessen vetni. Habár a járványnak még messze nincsen vége, és egyre újabb és újabb mutánsok ütik fel a fejüket a világ legkülönbözőbb részein, mégis azokat a tanulságokat, melyek már összegyűltek a gyógyszeripar területén, érdemes összefoglalni. Talán még ennél is fontosabb azonban, hogy azokat a hiányokat, amelyeket még be kell pótolni, szintén megemlítsük, hogy ezzel is segítsük az újabb hullámok vagy járványok leküzdését.

Summary. During the last 12 months the most serious issue was the SARS-CoV-2 virus generated pandemia around the world. There is no country which could be more or less intact and a huge amount of resources was sacrificed to rescue people from the fatal outcome of this disease. When it started a year ago or more, there were doubts about its future but later it was realised that this is an epidemic occurring worldwide, crossing international boundaries, and affecting a large number of people. According to the WHO, today the number of confirmed cases is about 157.8 million, confirmed deaths are 3.3 million and 1.2 billion vaccine doses have been administered. These numbers clearly show how important it is to elaborate the reaction of the pharma industry and investigate how to ensure safe drug supply for patients in every country. The topics discussed below are the basic and unique features of the SARS-CoV-2 virus, the pandemia generated by it, and the role of the Hungarian pharma industry, especially Gedeon Richter plc, during this critical period. On one hand the author explains how the spread of virus can be decreased in general and at a production facility like Richter, and on the other hand R&D activity of the Company aiming to cure patients suffering from COVID-19 infection. Consortia including universities, academia and industrial entities made a substantial impact on handling this terrible epidemic. Gedeon Richter plc, the biggest and only independent Hungarian pharma company, in keeping with its roots started small molecule R&D to make favipiravir and remdesivir available to clinics. The latter production is a very difficult one but using its background in chemistry Richter was able to manage all R&D and industrial scale up activities in six months. Moreover, it has filed two patent applications about its new, more feasible and economical process steps justifying its innovative attitude. As a final conclusion it is stated that for the safe supply of necessary medication one critical step is missing from the capabilities of the Hungarian pharma industry, the vaccine R&D and production.

  • 1

    Baraniuk, C. (2020) Receptors for SARS-CoV-2 Present in Wide Variety of Human Cells. TheScientist, https://www.the-scientist.com/news-opinion/receptors-for-sars-cov-2-present-in-wide-variety-of-human-cells-67496 (Letöltve: 2021. 05. 09.)

  • 2

    Guo, Q., Xu, M., Guo, S., Zhu, F., Xie, Y., & Shen, J. (2019) The complete synthesis of favipiravir from 2-aminopyrazine. Chemical Papers, Vol. 73, pp. 1043–1051.

  • 3

    Kacskovics, I. (2021) Magyar fejlesztésű gyógyszer a COVID ellen. https://www.elte.hu/content/magyar-fejlesztesu-gyogyszer-a-covid-ellen.t.22659 (Letöltve: 2021. 05. 09.)

  • 4

    Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., … Lessler, J. (2020) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Int. Med., Vol. 172. No. 9. pp. 577–582.

  • 5

    Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., … Mackman, R. L. (2017) Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1‑f ][triazin-4-amino] Adenine C‑Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem., Vol. 60. No. 5. pp. 1648–1661.

  • 6

    Szekanecz, Z., & Constantin, T. (2020) Citokinvihar Covid-19-fertőzésben. https://mta.hu/tudomany_hirei/citokinvihar-covid-19-fertozesben-110610 (Letöltve: 2021. 05. 09.)

  • 7

    Szlávik, J. (2021) Szlávik János: egy szuperfertőző maszk nélkül akár 100 embert is megfertőzhet zárt térben. https://budapestkornyeke.hu/szlavik-janos-egy-szuperfertozo-maszk-nelkul-akar-100-embert-is-megfertozhet-zart-terben/ (Letöltve: 2021. 05. 09.)

  • 8

    Yu, P., Zhu, J., Zhang, Z., & Han, Y. (2020) A Familial Cluster of Infection Associated With the 2019 Novel Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. J. Infect. Dis., Vol. 221 No. 11. pp. 1757–1761.

The author instructions are available in separate PDFs.
Please, download the Hungarian version from HERE, the English version from HERE.
The Submissions templates are available in MS Word.
For articles in Hungarian, please download it from HERE and for articles in English from HERE.
 

Ministry of Interior
Science Strategy and Coordination Department
Address: H-2090 Remeteszőlős, Nagykovácsi út 3.
Phone: (+36 26) 795 906
E-mail: scietsec@bm.gov.hu

2020  
CrossRef Documents 13
CrossRef Cites 0
CrossRef H-index 0
Days from submission to acceptance 247
Days from acceptance to publication 229
Acceptance Rate 36%

Publication Model Gold Open Access
Submission Fee none
Article Processing Charge none

Scientia et Securitas
Language Hungarian
English
Size A4
Year of
Foundation
2020
Publication
Programme
2020 Volume 1
Volumes
per Year
1
Issues
per Year
4
Founder Academic Council of Home Affairs and
Association of Hungarian PhD and DLA Candidates
Founder's
Address
H-2090 Remeteszőlős, Hungary, Nagykovácsi út 3.
H-1055 Budapest, Hungary Falk Miksa utca 1.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN ISSN 2732-2688

Editor-in-Chief:

  • Tamás NÉMETH 
    (Institute for Soil Sciences and Agricultural Chemistry, Centre for Agricultural Research
    Budapest, Hungary)

Managing Editor:

  • István SABJANICS (Ministry of Interior, Budapest, Hungary)

Editorial Board:

  • Melinda KOVÁCS (Szent István University Kaposvár Campus)Á
  • Miklós MARÓTH (Eötvös Loránd Research Network)
  • Charaf HASSAN (Budapest University of Technology and Economics)
  • Zoltán GYŐRI (Hungaricum Committee)
  • József HALLER (University of Public Service)
  • Attila ASZÓDI (Budapest University of Technology and Economics)
  • Zoltán BIRKNER (National Research, Development and Innovation Office)
  • Tamás DEZSŐ (Migration Research Institute)
  • Imre DOBÁK (University of Public Service)
  • András KOLTAY (University of Public Service)
  • Gábor KOVÁCS (University of Public Service)
  • József PALLO (University of Public Service)
  • Marcell Gyula GÁSPÁR (University of Miskolc)
  • Judit MÓGOR (Ministry of Interior National Directorate General for Disaster Management)
  • István SABJANICS (Ministry of Interior)
  • Péter SZABÓ (Hungarian University of Agriculture and Life Sciences (MATE))
  • Miklós SZÓCSKA (Semmelweis University)
  • János JÓZSA (Budapest University of Technology and Economics)
  • Valéria CSÉPE (Research Centre for Natural Sciences, Brain Imaging Centre)